Online inquiry

IVTScrip™ mRNA-Human ANKRD36B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16120MR)

This product GTTS-WK16120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ANKRD36B protein. This product can be used in SLC16A7+ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001353337.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 57730
UniProt ID Q8N2N9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANKRD36B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16120MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK7706MR IVTScrip™ mRNA-Human ADAMTS7, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADAMTS7
GTTS-WK16116MR IVTScrip™ mRNA-Human ANKRD30BP2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD30BP2
GTTS-WK22035MR IVTScrip™ mRNA-Human ARL14, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARL14
GTTS-WK13973MR IVTScrip™ mRNA-Human ACTR3B, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACTR3B
GTTS-WK22610MR IVTScrip™ mRNA-Human ARHGEF16, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARHGEF16
GTTS-WK23011MR IVTScrip™ mRNA-Human ASGR2, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASGR2
GTTS-WK21988MR IVTScrip™ mRNA-Human ARHGAP23, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP23
GTTS-WK6171MR IVTScrip™ mRNA-Human VWF, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VWF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW